Articles by Cecilia Brown
The phase 1 LuCa-MERIT-1 trial is evaluating BNT116, an unmodified RNA-based lipoplex cancer vaccine, with cemiplimab.
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Marina Garassino, MD, presented results from the phase 2 portion of the trial at the European Lung Cancer Congress.
Myung-Ju Ahn, MD, PhD, presented data from the study during the first proffered paper session of ELCC 2025.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.